Sol-Gel Technologies Research and Development Expenses 2016-2024 | SLGL
Sol-Gel Technologies research and development expenses from 2016 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Sol-Gel Technologies Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$24 |
| 2022 |
$13 |
| 2021 |
$20 |
| 2020 |
$28 |
| 2019 |
$41 |
| 2018 |
$28 |
| 2017 |
$26 |
| 2016 |
$17 |
| 2015 |
$7 |
Sol-Gel Technologies Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$5 |
| 2023-12-31 |
$4 |
| 2023-09-30 |
$5 |
| 2023-06-30 |
$5 |
| 2023-03-31 |
$9 |
| 2022-12-31 |
$4 |
| 2022-09-30 |
$2 |
| 2022-06-30 |
$2 |
| 2022-03-31 |
$4 |
| 2021-12-31 |
$5 |
| 2021-09-30 |
$6 |
| 2021-06-30 |
$7 |
| 2021-03-31 |
$2 |
| 2020-12-31 |
$6 |
| 2020-09-30 |
$8 |
| 2020-06-30 |
$6 |
| 2020-03-31 |
$8 |
| 2019-12-31 |
$8 |
| 2019-09-30 |
$10 |
| 2019-06-30 |
$11 |
| 2019-03-31 |
$11 |
| 2018-12-31 |
$11 |
| 2018-09-30 |
$7 |
| 2018-06-30 |
$6 |
| 2018-03-31 |
$5 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$4 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.020B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
